title: [Antiatherogenic and nephroprotective efficacy of atorvastatin in patients with chronic renal disease of non-diabetic origin].
abstract: This study designed to elucidate dynamics of lipid metabolism and HbA(1c) level, uricemia, and renal function in 54 patients with chronic renal disease (CRD) of non-diabetic genesis treated by standard cardioprotective therapy in combination with atorvastatin. The patients were divided in two groups with glomerular filtration rate (GFR) < 60 ml/min (n = 31) and = > 60 ml/min. The former were given 20 mg atorvastatin/day. Arterial pressure (AP): systolic (SAP), diastolic (DAP), and pulse (PAP) pressure, plasma lipid profile, uricemia, HbA(1c) and GFR were measured at admission and 6 months after the onset of therapy. The use of atorvastatin in combined therapy of CRD of non-diabetic genesis resulted in a significant decrease of the levels of atherogenic lipids, HbA(1c), uricemia, lipid peroxidation, SAP and PAP (by 4-5 mm Hg) while the initially low GFR (< 60 ml/min) increased. It is concluded that therapy of chronic renal disease of non-diabetic genesis with atorvastatin not only improves lipid metabolism but also decreases HbA(1c) level and uricemia, normalizes AP and renal function.
authors.forename: T N
authors.initials: TN
authors.lastname: Salomenchuk
authors.forename: K V
authors.initials: KV
authors.lastname: Semegen-Bodak
authors.forename: n A
authors.initials: nA
authors.lastname: Slaba
authors.forename: G V
authors.initials: GV
authors.lastname: Chngrian
authors.forename: M B
authors.initials: MB
authors.lastname: Mysyshin
authors.forename: O M
authors.initials: OM
authors.lastname: Slabyĭ
mesh_terms: D000924:Anticholesteremic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000069059:Atorvastatin; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects; D006442:Glycated Hemoglobin / Q000037:antagonists & inhibitors / Q000378:metabolism; D006538:Heptanoic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007677:Kidney Function Tests; D050356:Lipid Metabolism / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D011758:Pyrroles / Q000008:administration & dosage / Q000627:therapeutic use*; D051436:Renal Insufficiency, Chronic / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D016896:Treatment Outcome
chemical_list: D000924:Anticholesteremic Agents; D000069059:Atorvastatin; D006442:Glycated Hemoglobin; D006538:Heptanoic Acids; D011758:Pyrroles; C517652:hemoglobin A1c protein, human